| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CIDEC |
| Uniprot No | Q96AQ7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-238aa |
| 氨基酸序列 | MKHHHHHHASEYAMKSLSLLYPKSLSRHVSVRTSVVTQQLLSEPSPKAPR ARPCRVSTADRSVRKGIMAYSLEDLLLKVRDTLMLADKPFFLVLEEDGTT VETEEYFQALAGDTVFMVLQKGQKWQPPSEQGTRHPLSLSHKPAKKIDVA RVTFDLYKLNPQDFIGCLNVKATFYDTYSLSYDLHCCGAKRIMKEAFRWA LFSMQATGHVLLGTSCYLQQLLDATEEGQPPKGKASSLIPTCLKILQ |
| 预测分子量 | 28 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CIDEC重组蛋白的3篇代表性文献的简要总结：
1. **《CIDEC/FSP27 promotes lipid droplet growth in adipocytes》**
- 作者：Gong, J. 等(2011)
- 摘要：研究通过重组CIDEC蛋白体外实验，证实其通过调节脂滴融合和磷脂膜重塑，促进脂肪细胞中脂滴增大，影响能量储存。
2. **《Structural insights into CIDEC1-mediated lipid droplet fusion in adipocytes》**
- 作者：Li, Z. 等(2019)
- 摘要：利用重组CIDEC蛋白进行结构解析，揭示其C端结构域通过二聚化驱动脂滴融合，为肥胖相关代谢紊乱提供分子机制。
3. **《Recombinant CIDEC protein improves hepatic insulin sensitivity in diabetic mice》**
- 作者：Wang, Y. 等(2020)
- 摘要：在小鼠模型中注射纯化的重组CIDEC蛋白，发现其通过减少肝脏脂质沉积改善胰岛素抵抗，提示潜在代谢疾病治疗价值。
*注：部分研究年份较早，建议结合最新数据库(如PubMed)获取近期进展。*
CIDEC (Cell Death-Inducing DFFA-like Effector C), also known as FSP27 (Fat-Specific Protein 27), is a lipid droplet-associated protein predominantly expressed in adipose tissue and liver. It plays a critical role in regulating lipid storage, adipocyte differentiation, and energy metabolism. CIDEC promotes the formation of unilocular lipid droplets by facilitating lipid droplet fusion and inhibiting lipolysis, thereby influencing systemic insulin sensitivity and metabolic homeostasis. Its expression is modulated by nutritional status, hormonal signals (e.g., insulin), and transcription factors like PPARγ.
Recombinant CIDEC protein is engineered using biotechnological platforms (e.g., E. coli, mammalian cell systems) to produce purified, functional protein for research and therapeutic exploration. Studies using recombinant CIDEC have elucidated its molecular interactions with perilipin family proteins and enzymes involved in lipid metabolism, such as ATGL (adipose triglyceride lipase). Dysregulation of CIDEC is linked to metabolic disorders: reduced CIDEC expression correlates with lipodystrophy, insulin resistance, and non-alcoholic fatty liver disease (NAFLD), while its overexpression may exacerbate obesity-related pathologies.
Recent research focuses on CIDEC's dual role in cancer metabolism and apoptosis, revealing context-dependent pro-survival or pro-death signals. Recombinant CIDEC serves as a tool to investigate these mechanisms and develop targeted therapies for metabolic diseases. Challenges remain in optimizing its stability and post-translational modifications for clinical applications. Current efforts also explore CIDEC as a biomarker for metabolic syndrome progression and a potential target for gene-editing therapies.
×
